AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bio-Rad Laboratories Inc. (BIO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

282.87

5.71 (2.06%)

At close: Feb 18, 2025, 3:59 PM

283.21

0.12%

After-hours: Feb 18, 2025, 07:00 PM EST

undefined% (undefined)

Bid	266.96
Market Cap	8.10B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-65.35
PE Ratio (ttm)	-4.33
Forward PE	n/a
Analyst	Buy

Ask	291.42
Volume	400,438
Avg. Volume (20D)	190,700
Open	275.50
Previous Close	277.16
Day's Range	275.50 - 284.99
52-Week Range	262.12 - 387.99
Beta	undefined

About BIO

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, ...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Feb 27, 1980

Employees 7,700

Stock Exchange NYSE

Ticker Symbol BIO

Website https://www.bio-rad.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for BIO stock is "Buy." The 12-month stock price forecast is $417.5, which is an increase of 47.60% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Bio-Rad Laboratories Inc. is scheduled to release its earnings on May 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 days ago

-1.92%

Bio-Rad Laboratories shares are trading lower afte... Unlock content with Pro Subscription

3 months ago

+2.86%

Bio-Rad Laboratories shares are trading higher after Citigroup maintained a Buy rating on the stock and raised its price target from $400 to $450.

News

23 hours ago · zacks.com

BIO Stock Might Rise Following the Offer to Acquire Stilla

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

5 days ago · zacks.com

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.

5 days ago · seekingalpha.com

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President...

6 days ago · zacks.com

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.90 per share, missing the Zacks Consensus Estimate of $2.93 per share. This compares to earnings of $3.10 per share a year ago.

6 days ago · businesswire.com

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

6 days ago · businesswire.com

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

1 week ago · prismmediawire.com

Oncocyte Prices $29.1 Million Equity Offering

IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements wit...

1 week ago · zacks.com

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.

3 weeks ago · businesswire.com

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...

Load More News